Leishmania tarentolae expressing CXCL‐10 as an efficient immunotherapy approach against Leishmania major‐infected BALB/c mice
- 20 September 2017
- journal article
- research article
- Published by Wiley in Parasite Immunology
- Vol. 39 (10)
Abstract
Summary: Recent findings have demonstrated the suitability of interferon‐gamma‐induced protein 10 (IP‐10) or CXCL‐10 as an immunotherapy tool in treatment of leishmaniasis. This chemokine can overcome Leishmania (L.) infection through inducing nitric oxide (NO) production for parasite elimination. This study was undertaken to investigate the therapeutic effects of recombinant Leishmania tarentolae expressing CXCL‐10 and an expression vector encoding CXCL‐10 (pcDNA‐CXCL‐10‐EGFP) in a model of BALB/c mice susceptible to infection by Leishmania major. The outcome of intervention was examined at 3 weeks post‐treatment by evaluating the parameters of parasite burden (PB), arginase activity, NO and various cytokines such as IFN‐γ, IL‐4, IL‐6 and IL‐10. The results have shown that despite the efficacy of CXCL‐10 expression vector as gene therapy, the live therapy strategy using L. tarentolae expressing CXCL‐10 was more effective in terms of decreasing PB. Nitric oxide production increased, especially in the live therapy approaches. Arginase activity also decreased in all regimens, which demonstrates the potency of the treatment. The overall cytokine production shifted in favour of Th1 responses in the treated mice. Altogether, recombinant L. tarentolae expressing CXCL‐10 represents a promising therapeutic strategy to improve treatment of cutaneous leishmaniasis.Keywords
Funding Information
- Pasteur Institute of Iran (IPI 705)
This publication has 65 references indexed in Scilit:
- IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccineBMC Microbiology, 2014
- Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral LeishmaniasisPLOS Neglected Tropical Diseases, 2013
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- TLR4 and NKT Cell Synergy in Immunotherapy against Visceral LeishmaniasisPLOS Pathogens, 2012
- Leishmania majorMPK7 Protein Kinase Activity Inhibits Intracellular Growth of the Pathogenic Amastigote StageEukaryotic Cell, 2010
- Leishmaniasis vaccine: Where are we today?Journal of Global Infectious Diseases, 2010
- Enhanced Leishmania braziliensis Infection Following Pre-Exposure to Sandfly SalivaPLOS Neglected Tropical Diseases, 2007
- L-arginine metabolism and its impact on host immunity against Leishmania infectionImmunologic Research, 2007
- CXCL10/Gamma Interferon-Inducible Protein 10-Mediated Protection againstLeishmania amazonensisInfection in MiceInfection and Immunity, 2006
- iNOS-mediated nitric oxide production and its regulationLife Sciences, 2004